deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT04740905

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion (BALATON)

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion

Sponsor: Chugai Pharmaceutical

Conditions Branch Retinal Vein Occlusion Macular Edema
Interventions Aflibercept Faricimab Sham Procedure
Updated 24 times since 2021 Last updated: Jul 11, 2024 Started: Mar 2, 2021 Primary completion: Jul 6, 2022 Completion: Jun 12, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04740905, this PHASE3 trial focuses on Branch Retinal Vein Occlusion and Macular Edema and remains completed. Sponsored by Chugai Pharmaceutical, it has been updated 24 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Jun 2022 · 3 months · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Apr 2023 · 3 months · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jul 2023 · 2 months · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Feb 2024 · 6 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

24 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Feb 2024 — Jul 2024 [monthly]

    Completed PHASE3

  5. Aug 2023 — Feb 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

▶ Show 19 earlier versions

  1. Jul 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE3

  2. May 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE3

  3. Apr 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE3

  4. Jan 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE3

  5. Dec 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE3

  6. Sep 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE3

  7. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  8. Jun 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE3

  9. Mar 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  10. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE3

  11. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE3

  12. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

  13. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  14. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

  15. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

  16. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  17. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE3

  18. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  19. Mar 2021 — Apr 2021 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Chugai Pharmaceutical
  • Hoffmann-La Roche
Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abilene, United States , Aichi, Japan , Augusta, United States , Austin, United States , Barcelona, Spain , Beijing, China , Belfast, United Kingdom , Bellaire, United States , Blumenau, Brazil , Boston, United States and 124 more locations